What do systematic reviews say?

Deferasirox vs deferiprone (DFO)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 195 participants
  Very low

Deferasirox vs deferiprone (DFO)

• Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
  0.96 [0.06, 15.42]
  2 studies · 240 participants
  Very low

Hydroxyurea vs placebo

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 142 participants
  Very low

Angiotensin‐converting enzyme inhibitors vs vitamin C

The review found no eligible studies for this question.

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

The review found no eligible studies for this question.

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

The review found no eligible studies for this question.

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hydroxyurea vs placebo

Hydroxyurea showed no clear difference in serious adverse events compared with placebo (low certainty).

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  RR 0.39 [0.13, 1.16]
  1 study · 193 participants
  Low

Hydroxyurea vs placebo

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 193 participants
  Low

Hydroxyurea vs placebo

The review found no eligible studies for this question.

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Angiotensin‐converting enzyme inhibitors vs placebo

The review found no eligible studies for this question.

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

The review found no eligible studies for this question.

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

The review found no eligible studies for this question.

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

• Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 170 participants
  Very low

Lifestyle interventions vs placebo or usual care

• Interventions for weight reduction in obesity to improve survival in women with endometrial cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  Low

Lifestyle interventions vs placebo or usual care

It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes overall survival (24 months) compared with usual care compared to placebo (very low certainty).

• Interventions for weight reduction in obesity to improve survival in women with endometrial cancer 2023 · Cochrane Headline outcomes only
  RR 0.23 [0.01, 4.55]
  1 study · 37 participants
  Very low

Lifestyle interventions vs placebo or usual care

It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).

• Interventions for weight reduction in obesity to improve survival in women with endometrial cancer 2023 · Cochrane Headline outcomes only
  RR 19.03 [1.17, 310.52]
  8 studies · 315 participants
  Very low

Lifestyle interventions vs placebo or usual care

• Interventions for weight reduction in obesity to improve survival in women with endometrial cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 5 participants
  Low

Lifestyle interventions vs placebo or usual care

• Interventions for weight reduction in obesity to improve survival in women with endometrial cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 209 participants
  Low

Lifestyle interventions vs placebo or usual care

Summary of findings table ‐ Lifestyle intervention showed no clear difference in cardiovascular and metabolic event frequency (6 months) compared with usual care compared to placebo (low certainty).

• Interventions for weight reduction in obesity to improve survival in women with endometrial cancer 2023 · Cochrane Headline outcomes only
  RR 3.47 [0.15, 82.21]
  5 studies · 211 participants
  Low